TABLE I.
Treatment group | Low grade PIN | High grade PIN | Microinvasive carcinoma | ||||||
---|---|---|---|---|---|---|---|---|---|
wt (control; age 6 months) | 0.4 ± 0.1 | ** | 0.0 ± 0.0 | ** | ** | 0.0 ± 0.0 |
** * |
||
Min (age 6 months) | 1.5 ± 0.31 | 1.2 ± 0.20 | 1.0 ± 0.21 | * | * | ||||
Min (age 6 months) + anti-TNF | 1.6 ± 0.30 | 1.1 ± 0.31 | 0.6 ± 0.16 | ||||||
Min (age 6 months) + TREG | 1.7 ± 0.30 | 1.1 ± 0.31 | 0.4 ± 0.16 | ||||||
Min (age 3 months) untreated | 1.6 ± 0.30 | 0.9 ± 0.34 | 0.2 ± 0.13 | ||||||
Min (age 3 months) + sham IgG | 1.4 ± 0.22 | 0.5 ± 0.16 | * | 0.3 ± 0.15 | * | ||||
Min (age 3 months) + anti-CD25 IgG | 1.5 ± 0.30 | 1.6 ± 0.16 | 1.0 ± 0.21 |
Frequency and features of prostate lesions are given in this table. CD25+ cells are important in impeding age-related progression of neoplasia in the prostate of Min mice. Min mice depleted of CD25+ cells (N = 8 mice per trial) from age 1 to 3 months had significantly more HGPIN and microinvasive carcinoma prostate lesions when compared to agematched sham antibody treated (N = 8 mice per trial) control Min mice. Min mice that received supplemental CD25+ TREGS (N = 5 mice) showed a statistically significant decrease in the frequency of microinvasive carcinoma lesions when compared to Min mice of matched age = 6 months (N = 5 mice). Grading of neoplastic progression in the DLP of mice and analysis of results was performed as described in Material and methods.
p < 0.05;
p < 0.01;
p < 0.001.